Theranexus SA (FR:ALTHX) has released an update.
Theranexus SA, a biopharmaceutical company, has reported a significant reduction in operating expenses for the first half of 2024, primarily due to the conclusion of a phase 1/2 clinical trial and a rigorous cost-cutting policy. This led to a considerable decrease in other purchases, external charges, and wage costs, resulting in a slight profit for the period compared to a loss in the previous year. The company’s cash position suggests operational activities funding is secure until at least the first quarter of 2025.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.
